Brain zaps aim to smooth out motor struggles in autism
NCT ID NCT06497920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether autistic adults have too much 'plasticity' (flexibility) in the part of the brain that controls movement, and if a non-invasive brain stimulation technique called rTMS can reduce that over-plasticity to improve motor function. Researchers will compare brain activity and movement skills in 150 autistic and non-autistic adults aged 18-40. The goal is to understand the brain mechanisms behind motor difficulties, not to cure autism.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: ASD or control participants must meet all of the inclusion criteria to eligible for this study: 1. Aged between 18 and 40 years old. 40 years is chosen as the cut-off because of the report of high rates of Parkinsonism in autistic adults \> 39years; 2. Have IQ\>70; 3. Are able to read, write and communicate effectively in English; 4. Are able to provide informed consent. We will recruit only intellectually-able autistic adults. The intellectual ability will be determined using WASI-II. The ability to provide consent will be determined using clinical assessment. 5. Have no prior history of seizure; 6. Must sign and date the informed consent form; 7. Stated willingness to comply with all study procedures; 8. Agreement to adhere to Lifestyle Considerations, that is: refrain from consumption of alcohol, tobacco, marijuana, or caffeine on the day of study visits. All ASD participants: 1. Will have DSM-5 diagnosis of ASD without intellectual disability, confirmed by clinical assessment and the Autism Diagnostic Observation Schedule - 2 (ADOS-2); 2. Will have significant motor function difficulties defined as a standard composite score \<40 (i.e., \>1 standard deviation below the mean) on either fine or gross motor composite scores of the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition or BOT-2; 3. Are clinically stable as determined by clinical assessment, with no medication changes over the past 4 weeks. Given the high variability of handedness in ASD, we will include participants with left, right or mixed handedness. Exclusion Criteria: ASD or control participants will be excluded if they experience/have: 1. Current pregnancy; 2. Current or past history of co-morbid medical condition that may require urgent medical intervention; 3. DSM-5 substance use disorder (other than tobacco) within the past 6 months; however, all participants will be asked to refrain from smoking or taking caffeine four hours prior to the iTBS session; 4. Significant hearing or visual impairment interfering with the ability to read or hear instructions; 5. Significantly debilitating medical or neurologic illness (e.g., encephalitis, aneurysms, tumors, central nervous system infections), or acute or unstable medical illnesses as determined by project physician (e.g., uncontrolled diabetes); 6. Metal implants or a pace-maker; 7. Prior rTMS treatment; In addition, ASD participants will be excluded if they report taking benzodiazepines or anticonvulsants currently. NT controls will be excluded if they have: 1. Presence of psychopathology other than specific phobia, as screened by Personality Assessment Inventory and; 2. A known diagnosis of Pervasive Developmental Disorder or ASD among any biologically related family members.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Center for Addiction and Mental Health (CAMH)
RECRUITINGToronto, Ontario, M6J 1H4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can wireless monitors make ER vitals easier for autistic children?
- Why do some children with autism struggle with balance?
- Brain zaps tested to calm emotional storms in autism
- Can an AI chatbot help autism caregivers find their way?
- Pregnancy and birth clues: what raises autism risk?
- Can virtual reality boost thinking skills in kids with autism?